2021 Marked New Era Of Domestic Collaboration in China
But M&A Outlook Still Muted?
Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.
You may also be interested in...
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.